News & Updates
Updates, press releases, and news on our work on GB-13.
Targepeutics Inc is proud to announce that the U.S. Food and Drug Administration (FDA) has granted Pediatric Rare Disease Designation (RPDD) for its investigational immunotoxin therapy, GB13 (IL13-E13K-PE4E). This breakthrough…
Read More
The Focused Ultrasound (FUS) Foundation has awarded funding to support the Preclinical Brain Project Focused Ultrasound Promotes Blood-Brain Barrier Opening and Delivery of GB13 to Pediatric High-Grade Gliomas. The collaborative…
Read More
Sil Lutkewitte, Chief Executive Officer, and Randy Schrecengost, Chief Scientific Officer, at Targepeutics had the opportunity to join Mark Levine as guests on his podcast ‘ Help and Hope Happen…
Read More
Targepeutics is presenting the latest preclinical data related to ongoing development of the novel immunotoxin, GB13, for the treatment of GBM. This data will presented as a poster presentation during…
Read MorePenn State University College of Medicine, Department of Neurosurgery and Targepeutics are pleased to announce that they have been awarded a W.W. Smith Charitable Trust Medical grant. This grant will…
Read More
Targepeutics is presenting the latest efficacy data related to treatment of GBM and DMG tumors with the novel immunotoxin, GB13. This data is presented as a poster presentation during the…
Read More
Targepeutics announces a Phase I Small Business Innovation Research (SBIR) grant awarded to Dr Randy Schrecengost as Primary Investigator to support preliminary data demonstrating that GB13 can specifically target IL13Rα2-positive…
Read More